Tary Traore
Blueprint Medicines (United States)(US)
Publications by Year
Research Areas
Ubiquitin and proteasome pathways, Protein Degradation and Inhibitors, Histone Deacetylase Inhibitors Research, Cancer-related Molecular Pathways, 14-3-3 protein interactions
Most-Cited Works
- → An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer(2009)1,965 cited
- → A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment(2018)441 cited
- → MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma(2010)321 cited
- → Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924(2012)108 cited
- → Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia(2018)87 cited
- → Azacitidine/Decitabine Synergism with the NEDD8-Activating Enzyme Inhibitor MLN4924 in Pre-Clinical AML Models(2011)26 cited
- → Antitumor activity of MLN4924, an investigational inhibitor of NEDD8-activating enzyme (NAE), in preclinical models of melanoma.(2011)7 cited
- → Abstract LB-294: Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2(2018)6 cited
- → 255 Pre-clinical in vivo characterization of MLN7243, an investigational ubiquitin activating enzyme inhibitor, in solid tumor models(2014)4 cited
- → Abstract 1717: MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models(2021)3 cited